Press

Wesana Announces Second Quarter 2022 Financial Results

Aug 30 • 5 min read

Wesana Health Holdings Inc. (CSE: WESA | OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its second quarter 2022 financial results. H1 2022 Highlights Received positive feedback from pre-Investigational New Drug (“IND”) meeting with U.S. Food and Drug Administration (“FDA”) on SANA-013…

Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo Branded Ingredient from FDA

Aug 29 • 4 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (‘KGK’) provided regulatory guidance and expertise on behalf of its client, Hofseth…

PharmAla Biotech completes filing of Patent application for 6 MDMA analogs

Aug 29 • 4 min read

PharmAla Biotech (CSE: MDMA) is pleased to announce the filing of a key Patent Cooperation Treaty (PCT) application, containing 6 Novel Chemical Entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. This PCT application disclosed novel compositions of MDMA and analogs thereof which may be used to alleviate…

MindMed Completes 1-for-15 Reverse Share Split

Aug 29 • 3 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its previously announced 1-for-15 reverse share split of the Company’s common shares, par value $0.001, became effective after the close of markets on August 26, 2022, with trading expected to begin on a…

Love Pharma Delivers Letter to Shareholders

Aug 29 • 5 min read

LOVE Pharma Co. (CSE: LUV | FSE: G1Q0), the Company is pleased to provide the following letter to shareholders, outlining the Company’s advancements with key holdings and its strategy for the future. To the Shareholders of Love Pharma: We welcome this opportunity to provide our shareholders with a comprehensive picture of Love’s efforts in building upon…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441